CE 245677
Alternative Names: CE-245677Latest Information Update: 16 Jul 2016
At a glance
- Originator Pfizer
- Class Antineoplastics
- Mechanism of Action TIE-2 receptor antagonists; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammatory pain
- Discontinued Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-pain in United Kingdom (PO)
- 13 Nov 2010 Preclinical trials in Inflammatory pain in United Kingdom (PO)
- 13 Nov 2010 Pharmacodynamics data from preclinical development in inflammatory pain presented at the 40th Annual Meeting of the Society for Neuroscience (SFN-2010)